Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Study of Apatinib Plus Radiotherapy and S-1 for Treatment of Refractory or Metastatic Esophageal Squamous Cell Carcinoma

NCT03320629 is registered in ClinicalTrials.gov with Hebei Medical University Fourth Hospital as lead sponsor.

NCT NCT03320629
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03320629 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Study of Apatinib Plus Radiotherapy and S-1 for Treatment of Refractory or Metastatic Esophageal Squamous Cell Carcinoma
Lead sponsor
Hebei Medical University Fourth Hospital
Phase
Phase 2
Overall status
Terminated
Start date
November 1, 2017
Completion date
December 31, 2018
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory or metastatic esophageal squamous cell carcinoma